Trial Profile
Efficacy and safety of acotumomab-alum vaccine (Vaxira(R)) as maintenance treatment of recurrent platinum-sensitive epithelial ovarian cancer (EOC)
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Racotumomab (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- 13 Mar 2015 New trial record